Table 1.
Characteristics of Patients With HCC Between SQLE High and SQLE Low Groups.
| Variables | SQLE Expression Level | P Value | |
|---|---|---|---|
| Low (n = 180) | High (n = 181) | ||
| Gender, male (%) | 117 (65.0) | 127 (70.2) | .294 |
| Age, median (IQR), years | 61 (18) | 60 (19) | .849 |
| BMI, kg/m2, n (%) | .491 | ||
| <18.5 | 13 (7.2) | 8 (4.4) | |
| 18.5-24.99 | 75 (41.7) | 77 (42.5) | |
| 25-29.99 | 42 (23.3) | 46 (25.4) | |
| >30 | 38 (21.1) | 29 (16.0) | |
| Race, n (%) | .14 | ||
| Asian | 70 (38.9) | 86 (47.5) | |
| White | 96 (53.3) | 80 (44.2) | |
| Black or African American | 7 (3.9) | 11 (6.1) | |
| Tumor status, n (%) | .415 | ||
| With tumor | 51 (28.3) | 58 (32.0) | |
| Tumor free | 117 (65.0) | 110 (60.8) | |
| Family history of cancer, n (%) | 56 (31.1) | 53 (29.3) | .705 |
| Hepatocarcinoma risk factors, n (%) | .255 | ||
| Hepatitis virus infection | 50 (27.8) | 61 (33.7) | |
| Alcohol consumption | 36 (20.0) | 34 (18.8) | |
| Hepatitis virus plus alcohol consumption | 25 (13.9) | 14 (7.8) | |
| Nonalcoholic fatty liver disease | 8 (4.4) | 7 (3.9) | |
| No risk factors | 38 (21.1) | 48 (26.5) | |
| Neoplasm histologic grade, n (%) | .036 | ||
| G1 | 28 (15.6) | 25 (13.8) | |
| G2 | 87 (48.3) | 84 (46.4) | |
| G3 | 60 (33.3) | 61 (33.7) | |
| G4 | 1 (0.6) | 11 (6.1) | |
| AJCC stage, n (%) | .045 | ||
| I | 78 (43.3) | 89 (49.2) | |
| II | 49 (27.2) | 33 (18.2) | |
| III | 33 (18.3) | 51 (28.2) | |
| IV | 1 (0.6) | 3 (1.7) | |
| Vascular invasion, n (%) | .362 | ||
| Macro | 9 (5.0) | 7 (3.9) | |
| Micro | 49 (27.2) | 40 (22.1) | |
| None | 98 (54.4) | 102 (56.4) | |
| Child-Pugh classification, n (%) | .784 | ||
| A | 105 (58.3) | 107 (59.1) | |
| B | 10 (5.6) | 11 (6.1) | |
| C | 1 (0.6) | 0 (0) | |
| NA | 64 (35.6) | 63 (34.8) | |
| AFP > 400 ng/mL, n (%) | 24 (13.3) | 40 (22.1) | .029 |
| Platelet, ×103/mm3, n (%) | .98 | ||
| <100 | 9 (5.0) | 7 (3.9) | |
| 100-199 | 62 (34.4) | 51 (28.2) | |
| 200-299 | 49 (27.2) | 46 (25.4) | |
| 300-399 | 14 (7.8) | 14 (7.8) | |
| >400 | 24 (13.3) | 20 (11.0) | |
| New tumor event after initial treatment, n (%) | 46 (25.6) | 47 (26.0) | .929 |
| Ishak fibrosis status, n (%) | .676 | ||
| No fibrosis | 32 (17.8) | 40 (22.1) | |
| Portal fibrosis | 17 (9.4) | 14 (7.8) | |
| Fibrous septa | 13 (7.2) | 15 (8.3) | |
| Nodular formation/incomplete cirrhosis | 5 (2.8) | 4 (2.2) | |
| Cirrhosis | 39 (21.7) | 31 (17.1) | |
| NA | 74 (41.1) | 77 (42.5) | |
| Hepatic inflammation, n (%) | .9 | ||
| None | 60 (33.3) | 54 (29.8) | |
| Mild | 54 (30.0) | 43 (23.8) | |
| Severe | 10 (5.6) | 8 (4.4) | |
| NA | 56 (31.1) | 76 (42.0) | |
| Follow up, median (IQR), years | 0.41 (1.8) | 0.27 (1.4) | .116 |
Abbreviations: AJCC, American Joint Committee on Cancer; AFP, α-fetoprotein; BMI, body mass index; HCC, hepatocellular carcinoma; IQR, interquartile range; NA, not available; SQLE, squalene epoxidase.